A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway
Citations Over TimeTop 12% of 2011 papers
Abstract
Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily that plays a key role in the regulation of differentiation, activation and survival of osteoclasts and also in tumor cell migration and bone metastasis. Osteoclast activation induced by RANKL regulates hematopoietic stem cell mobilization as part of homeostasis and host defense mechanisms thereby linking regulation of hematopoiesis with bone remodeling. Binding of RANKL to its receptor, Receptor activator of nuclear factor-kappa B (RANK) activates molecules such as NF-kappa B, mitogen activated protein kinase (MAPK), nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). Although the molecular and cellular roles of these molecules have been reported previously, a systematic cataloging of the molecular events induced by RANKL/RANK interaction has not been attempted. Here, we present a comprehensive reaction map of the RANKL/RANK-signaling pathway based on an extensive manual curation of the published literature. We hope that the curated RANKL/RANK-signaling pathway model would enable new biomedical discoveries, which can provide novel insights into disease processes and development of novel therapeutic interventions.
Related Papers
- → TNF‑α and RANKL promote osteoclastogenesis by upregulating RANK via the NF‑κB pathway(2018)144 cited
- → Monosodium Urate in the Presence of RANKL Promotes Osteoclast Formation through Activation of c‐Jun N‐Terminal Kinase(2015)21 cited
- → The effects of tumor necrosis factor-α on osteoclast formation depend on the haematopoietic precursors(2006)
- 64Cu-RGD and microPET/CT as an imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation(2009)
- → Inhibitory Effect of Agrocybe Chaxingu (Chaxines) on RANKL-Induced Osteoclast Differentiation in RAW246.7 Cells: Possible Prevention of Osteoporosis(2022)